Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.27    
    

COMPENSATION OF NAMED EXECUTIVE OFFICERS  

	Named Executive Officer
 
	 	2006 Bonus
	 	2007 Annual Base Salary*

	Safi R. Bahcall, Ph.D. President and Chief Executive Officer	 	$	100,000	 	$	355,000
	Keith S. Ehrlich, C.P.A. Vice President, Finance and Administration, Chief Financial Officer	 	$	44,000	 	$	230,000
	James G. Barsoum, Ph.D. Senior Vice President, Research	 	$	46,000	 	$	240,000
	Eric W. Jacobson, M.D. Senior Vice President, Clinical Research and Regulatory Affairs, Chief Medical Officer	 	$	65,000	 	$	280,000
	Keizo Koya, Ph.D. Senior Vice President, Drug Development	 	$	52,000	 	$	270,000

	*
	Effective
March 1, 2007. 

QuickLinks

Exhibit 10.27Exhibit 10.98

PATENT ASSIGNMENT AGREEMENT

THIS
PATENT ASSIGNMENT AGREEMENT is made and entered into this 5th day of
February, 2007 (this “Agreement”), by and between ADVANCED CELL
TECHNOLOGY, INC., a Delaware corporation duly organized under law (“Assignee”),
and INFIGEN, INC., a Delaware corporation duly organized under law (“Assignor”).

RECITALS

Assignor
owns the patent applications and issued patents listed on Schedule 1
attached hereto and all divisions, continuations, renewals, reissues and
extensions thereof worldwide (collectively, the “Patents”), and has
agreed to sell, transfer, assign, deliver and otherwise convey to Assignee all
of Assignor’s right, title, and interest in, to, and under the Patents.  The Assignee has agreed to acquire the
Patents in accordance with the terms of this Agreement.  Assignor hereby confirms this assignment for
purposes of filing the same with the United States Patent and Trademark Office
and foreign counterparts thereto.

The
parties therefore agree as follows:

1.             In consideration of the payment of
One Hundred Thousand ($100,000.00) Dollars and Eight Hundred Thousand (800,000)
shares of common stock of Assignee (“Common Stock”), each in accordance with
Sections 4 and 5 below, and for other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, accepted and agreed
to, Assignor hereby sells, transfers, assigns, delivers and otherwise conveys
and sets over unto Assignee, and Assignee hereby accepts, all of Assignor’s
rights, title, and interest in, to, and under the following:

A.            The Patents; and

B.                                     All proceeds of
the foregoing, including, without limitation, any claim by Assignor against
third parties for past, present, or future infringement of the Patents.

2.             Assignor agrees that, upon Assignee’s
reasonable request, it will, at any time without charge to Assignee, sign all
papers, take all rightful oaths, and do all acts which may be necessary,
desirable or convenient (as determined in Assignee’s sole reasonable
discretion) for vesting title to the Patents in Assignee, its successors,
assigns and legal representatives or nominees, including but not limited to,
any acts which may be necessary, desirable or convenient for claiming said
rights and for securing and maintaining the Patents, as applicable, in any and
all countries and for vesting title thereto in Assignee.  Assignor hereby appoints Assignee and any
officer or agent thereof, with full power of substitution, as its true and
lawful attorney-of-fact with full irrevocable power and authority in place and
stead of Assignor and in the name of Assignor or in its own name, for the
purposes of carrying out the terms of this Agreement, to take any and all
appropriate actions and to execute any and all documents and instruments which
may be necessary or desirable to accomplish the purposes of this
Agreement.  Furthermore, Assignor agrees
that, upon Assignee’s reasonable request, it will cooperate fully with Assignee
in the protection and enforcement of the Patents, including but not limited to,
cooperating fully with Assignee in connection with any claims or suits brought
by or against Assignee relating to the Patents, with all reasonable
out-of-pocket expenses, if any, to be borne by Assignee. This Agreement
expressly grants to Assignee all rights in the Patents as fully and entirely as
the same would have been held and enjoyed by Assignor.

3.             Without limiting the generality of
the foregoing, Assignor agrees concurrently with the execution of this
Agreement to execute an assignment of patent substantially in the form of the
assignment of patent included on Schedule 2 attached hereto for
recordation in the United States Patent and Trademark Office.

1

 

4.             As consideration for the Patents,
(a) upon execution of this Agreement by Assignor and Assignee, Assignee shall
concurrently pay the Assignor Seventy Five Thousand ($75,000.00) Dollars via
wire transfer to the Whyte Hirschboeck Dudek S.C. Attorneys-at-Law Trust
Account, in accordance with the wire instructions set forth in Schedule 3
attached hereto, with reference to “23027-0004” and (b) on or prior to April 1,
2007, Assignee shall pay Assignor Twenty Five Thousand ($25,000.00) Dollars via
wire transfer to the same Trust Account in the same manner (i.e., in accordance
with the wire instructions set forth in Schedule 3.)

5.             As further
consideration for the patents, upon execution of this Agreement, Assignee shall
issue Eight Hundred Thousand (800,000) shares of Common Stock of Assignee to
the persons (the “Holders”) and in the amounts set forth below:

	
   

  	
   

  	
  Shares

  	
   

  
	
  Eric Postel

  	
   

  	
  57,778

  	
   

  
	
  Foley & Lardner, LLC

  	
   

  	
  251,433

  	
   

  
	
  Ardshiel, Inc.

  	
   

  	
  176,800

  	
   

  
	
  Walter Simson

  	
   

  	
  113,989

  	
   

  
	
  Aquetong Capital Advisors, Inc.

  	
   

  	
  200,000

  	
   

  

 

Each
of the Holders has delivered to Assignee a Subscription Agreement substantially
in the form set forth in Schedule 4 attached hereto.

6.             If following the date of this
Agreement and prior to one year from the date of this Agreement, Assignee shall
determine to file a registration statement to register any of its Common Stock
under the Securities Act of 1933, as amended, for sale in connection with a
public offering of its Common Stock (other than pursuant to an employee benefit
plan or a merger, acquisition or similar transaction), whether for its own
account or for the account of one or more shareholders of Assignee, Assignee
will give prompt written notice thereof to each of the Holders and shall use
its commercially reasonable best efforts to include in such registration
statement any or all of the shares of Common Stock which a Holder may request
be included therein (the “Included
Shares”) by a writing delivered to Assignee within 15 days after the
notice given by Assignee to each Holder; provided, however, that Assignee shall
not be required to include such Included Shares, or a portion thereof, if
applicable, in any registration statement filed by Assignee if at any time
(a)  a representative of the underwriters of the offering refuses in
writing to include in the offering all or a portion of the Included Shares
requested to be included therein by the Holders, or (b) inclusion of the
Included Shares in any such registration statement would violate or cause a
breach of the terms and conditions of any currently existing or future
financing transaction entered into by Assignee.

7.             The Patents are being sold,
transferred and assigned to Assignee, on an “As-Is, Where-Is” basis without any
representations or warranties of any nature or kind and none are made or
intended.  Assignor accordingly disclaims
any representations or warranties pertaining to the validity, invalidity,
infringement or non-infringement of the Patents, or to the priority or
patentability of the inventions embodied therein.  This Agreement constitutes the entire
understanding between the parties with respect to the Patents.

8.             Assignee acknowledges and agrees
that the assignment of rights in Section 1 of this Agreement is subject to that
certain License and Settlement Agreement entered into by Infigen, Inc. and
Pharming Group N.V. (as executed by Infigen and Pharming Group N.V. on July 13,
2004 and July 9, 2004, respectively).

9.             Assignor acknowledges and agrees
that upon execution of this Agreement by the parties, Assignee may issue a
press release that discloses this Agreement and the terms and conditions of
this

2

 

Agreement, and further, that Assignee may make any
disclosure of this Agreement and the terms and conditions of this Agreement as
is required by applicable law, including without limitation, state and federal
securities laws or regulations.

10.           This Agreement may be amended and any
of its terms or conditions may be waived only by a written instrument executed
by an authorized signatory of the parties or, in the case of a waiver, by the
party waiving compliance.

11.           This Agreement may be executed in any
number of counterparts, each of which will be deemed an original, but all of
which together will constitute but one and the same instrument.

12.           This Agreement shall be governed by
and construed and enforced in accordance with the laws of New York

3

 

IN WITNESS
WHEREOF, the parties have caused this Agreement to be duly executed and
authorized as of the date first written above.

	
  

  	
  INFIGEN, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Dennis McCormick

  
	
   

  	
  Name: Dennis McCormick

  
	
   

  	
  Title: Chairman

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  ADVANCED CELL TECHNOLOGY, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ William M. Caldwell, IV

  
	
   

  	
  Name: William M. Caldwell, IV

  
	
   

  	
  Title: Chairman and C.E.O.

  

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]